Corporate Banner
Satellite Banner
Technology
Networks
Scientific Communities
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Eyevensys Announces an Equity Investment by Boehringer Ingelheim Venture Fund

Published: Thursday, April 11, 2013
Last Updated: Thursday, April 11, 2013
Bookmark and Share
Dr Michel Pairet, Boehringer Ingelheim's head of non-clinical research and development, joins Eyevensys’ board of directors.

Eyevensys, a developer of a new process for non-viral gene therapy using electrotransfer that enables prolonged production of therapeutic proteins for the treatment of ocular disease, today announces an equity investment by the Boehringer Ingelheim Venture Fund (BIVF). It also announces that Dr Michel Pairet, Boehringer Ingelheim's head of non-clinical research and development, has been appointed to its board of directors.

This equity investment by BIVF marks the start of Eyevensys' next round of funding, which is planned to take place before the end of the second quarter of 2013 and aims to fund the business through to completion of Phase IIa clinical trials. The Eyevensys investment is BIVF's sixth since its launch in 2010 and its first investment in a French company. BIVF had previously taken a stake in Inserm Transfert Initiative, an investment company specializing in seed capital for start-ups coming out of academic research and a past investor in Eyevensys.

The company's past investors (Innobio, managed by CDC Entreprises, Inserm Transfert Initiative and CapDecisif Management) also intend to participate in this second round of funding. Eyevensys raised EUR 1.6 million from its first round of funding in January 2012.

“Boehringer Ingelheim Venture Fund's equity investment brings us credibility, further raises our profile and gives us access to their wealth of experience in pharmaceutical and biotechnology R&D. This sends a strong signal to our target market,” said Dr Ivan Cohen-Tanugi, chairman of Eyevensys. “Dr Michel Pairet is well known in our industry. His experience, combined with the experience of the BIVF team, will undoubtedly help us to strengthen our development. We plan to complete a new round of funding between now and June. Discussions are already underway with potential new investors.”

The aim of this second round is to allow the company to finalize its preclinical trials, proceed to clinical trials within 18 months and complete Phase IIa. Eyevensys is currently focusing on two ophthalmological indications with significant unmet medical needs. These are: uveitis, a rare disease, and age-related macular degeneration, a pathology which occurs more frequently than uveitis and is becoming more prevalent as a result of population aging.

Eyevensys is the only company to have reached this advanced stage of investigation of novel treatment approaches for non-viral gene therapy. The technology developed by Eyevensys involves the electrotransfer of plasmids into the ciliary muscle resulting in a stable, sustained expression of therapeutic proteins. This new therapeutic approach will be less invasive than current therapies, as the frequency of injections can be greatly reduced from fortnightly or monthly to every six months potentially improving the quality of life of patients. Alongside higher efficacy it is hoped that the reduced doses of medication and proteins could also reduce side-effects. The first preclinical results in animal models have shown the expression of therapeutic proteins for up to nine months.

“Eyevensys' novel approach, which targets pathologies where few therapies are available and offers potential advantages in terms of effectiveness, administration and tolerability, makes it a perfect fit with the Boehringer Ingelheim fund's criteria for investment,” explains Dr Michel Pairet, head of non-clinical research and development at Boehringer Ingelheim. “In the future, medicine will increasingly rely on a combination of technologies, as we see here with the combination of gene therapy with a medical device.”

Michel Pairet has been with Boehringer Ingelheim since 1992. Before heading up the German company’s worldwide non-clinical research and development division, he was responsible for its worldwide research, and its corporate investment fund. Michel Pairet is a doctor of veterinary medicine and has a PhD in physiology and pharmacology.


Further Information
Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 2,400+ scientific posters on ePosters
  • More Than 3,700+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.

Related Content

Eyevensys Appoints Dr Ivan Cohen-Tanugi as CEO
Dr Ivan Cohen-Tanugi, with over 20 years’ experience in the international pharmaceutical industry, will prepare Eyevensys to launch clinical trials for the company’s non-viral gene therapy processes in two ophthalmic indications.
Tuesday, March 26, 2013
Scientific News
Study Finds Brain Chemicals that Keep Wakefulness in Check
Researchers to develop new drugs that promote better sleep, or control hyperactivity in people with mania.
Sorting Through Cellular Statistics
Aaron Dinner, professor in chemistry, and his graduate student Herman Gudjonson are trying to read the manual of life, DNA, as part of the Dinner group’s research into bioinformatics—the application of statistics to biological research.
Playing 'Tag' with Pollution lets Scientists See Who's It
Using a climate model that can tag sources of soot from different global regions and can track where it lands on the Tibetan Plateau, researchers have determined which areas around the plateau contribute the most soot — and where.
Women’s Immune System Genes Operate Differently from Men’s
A new technology reveals that immune system genes switch on and off differently in women and men, and the source of that variation is not primarily in the DNA.
Long Telomeres Associated with Increased Lung Cancer Risk
Genetic predisposition for long telomeres predicts increased lung adenocarcinoma risk.
First Artificial Ribosome Designed
Researchers at the University of Illinois at Chicago and Northwestern University have engineered a tethered ribosome that works nearly as well as the authentic cellular component, or organelle, that produces all the proteins and enzymes within the cell.
High-Resolution 3D Images Reveal the Muscle Mitochondrial Power Grid
NIH mouse study overturns scientific ideas on energy distribution in muscle.
Expanding the Brain
A team of researchers has identified more than 40 new “imprinted” genes, in which either the maternal or paternal copy of a gene is expressed while the other is silenced.
Identifying a Key Growth Factor in Cell Proliferation
Researchers discover that aspartate is a limiter of cell proliferation.
Study Uncovers Target for Preventing Huntington’s Disease
Scientists from Cardiff University believe that a treatment to prevent or delay the symptoms of Huntington’s disease could now be much closer, following a major breakthrough.
Scroll Up
Scroll Down
Skyscraper Banner

Skyscraper Banner
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
2,400+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
3,700+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FREE!